Based on the clinical success of tebentafusp and our preclinical results, we anticipate that the TYRP1 CAR-T cell therapy has the potential to benefit patients with uveal melanoma and overcome the HLA restriction, providing a clinical candidate for ~90% of patients with uveal melanoma. The gene discussed is TYRP1; the disease is uveal melanoma.